Navigation Links
Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
Date:7/7/2011

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

"This is the first prospective study to evaluate the treatment of venous thromboembolism (VTE) or blood clots in cancer patients and is a potentially practice-changing clinical trial," said principal investigator Dr. Myra Barginear, M.D., of The North Shore-LIJ Health System in New York, U.S.A. The inferior vena cava is a large blood vessel in the abdomen that carries blood from the lower parts of the body back to the heart. A thin-mesh IVC filter can be placed in the inferior vena cava to prevent blood clots, or VTEs, from reaching the heart.

In the study, sixty-four patients with deep venous thrombosis (86%) and/or pulmonary embolism (55%) received fondaparinux. About half of patients received only fondaparinux, while the other half received fondaparinux in conjunction with an IVCF.

The median survival for patients receiving only fondaparinux was 493 days, compared with 266 days for patients on fondaparinux plus an IVCF. Meanwhile, a median 52% of patients on fondaparinux alone experienced a complete resolution of VTEs, compared with 45% of patients on fondaparinux plus IVCF.

The study suggests that there is no benefit from costly and invasive IVCF placement in patients who are receiving fondaparinux. The results also support future randomized trials to compare VTE resolution rates achieved with fondaparinux with low molecular weight heparin, another class of anticoagulant medication.


'/>"/>

Contact: Rene McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Report finds large state disparities in progress against colorectal cancer
2. Lack of clarity about HPV vaccine and the need for cervical cancer screening
3. Patient Disparities Seen in Lung Cancer Drug Trials
4. Transcription factor is potential target for liver cancer treatment
5. U.S. Database of Breast Cancer Treatment May Be Inaccurate
6. What causes brain cancer?
7. Colon Cancer Death Rates Continue to Drop, CDC Reports
8. Canadas Cancer Risk Management model is an important new health tool for policymakers
9. Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
10. Increased investment in thoracic surgical expertise increased UK lung cancer resection rate
11. Metabolic shift may offer early cancer clue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has ... help provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, ... Nick Hallack, President and CEO of Medisend, parent organization and home of the General ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today ... workers across 15 states. The outcomes examined in these studies include recovery of ... and satisfaction with medical care. , “The goal of the studies is to ...
(Date:5/25/2016)... ... 2016 , ... Today Omega Institute, a leading destination for yoga education in ... opportunities in the growing field of yoga therapy . Yoga therapy adapts ... specific health issues—including injuries, illnesses, and temporary or chronic health conditions. , “Yoga therapy ...
(Date:5/25/2016)... Washington, D.C (PRWEB) , ... May 25, 2016 ... ... of family planning services and products in the developing world, is pleased to ... couples, helped prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Non-invasive diagnostic test realizes the ... ,Technology to be presented at Yissum’s booth, at IATI-BIOMED ... Company of the Hebrew University of Jerusalem announced ... Aurum Ventures MKI, the technology investment arm of Morris ... approach for early detection of multiple diseases by analyzing ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
(Date:5/23/2016)... STAMFORD, Conn. , May 23, 2016 /PRNewswire/ ... Company has entered into an agreement with Egalet ... various patent claims. As part of the agreement ... rights, and will enable all three companies to ... abuse-deterrent properties. "This agreement reflects the ...
Breaking Medicine Technology: